Literature DB >> 19115377

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Valérie Paradis1, Stéphane Zalinski, Emna Chelbi, Nathalie Guedj, Françoise Degos, Valérie Vilgrain, Pierre Bedossa, Jacques Belghiti.   

Abstract

UNLABELLED: Metabolic syndrome (MS) is a newly identified risk factor in chronic liver disease (CLD) and hepatocellular carcinoma (HCC). The aim of this study was to analyze the pathological characteristics of HCC and nontumoral liver in patients with MS as the only risk factor for liver disease in comparison with those that developed in the course of other CLDs in order to provide further insight into the physiopathology of HCC associated with MS. HCC patients with features of MS as the only risk factor for liver diseases (MS group, n = 31) were compared to HCC patients with overt causes of CLD (CLD group, n = 81) or without causes of CLD (cryptogenic group, n = 16) who underwent surgical resection during the same period of time. Among the patients of the MS group, there were 30 males and 1 female. In comparison with the patients with HCC of the CLD group, the patients with MS were older (mean age: 67+/- 7 versus 59 +/- 14 years, P < 0.01), and the background liver was significantly more often free of significant fibrosis (F0-F2: 65% in the MS group versus 26% in the CLD group, P < 0.001). In addition, HCCs associated with MS were more often well differentiated (65% versus 28%, P < 0.001). Five HCCs, all from the MS group, developed on a preexisting liver cell adenoma, with three of them showing typical histological features of telangiectatic adenoma.
CONCLUSION: This study shows that HCCs in patients with features of MS as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver. In addition, some of them arise through malignant transformation of a preexisting liver cell adenoma.

Entities:  

Mesh:

Year:  2009        PMID: 19115377     DOI: 10.1002/hep.22734

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  150 in total

Review 1.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 2.  [Lipid droplet-associated proteins. Importance in steatosis, steatohepatitis and hepatocarcinogenesis].

Authors:  B K Straub
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

3.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

Review 4.  Hepatic glucose sensing and integrative pathways in the liver.

Authors:  Maaike H Oosterveer; Kristina Schoonjans
Journal:  Cell Mol Life Sci       Date:  2013-11-07       Impact factor: 9.261

5.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

6.  Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.

Authors:  Noriyuki Koyama; Tomoko Yamazaki; Yuka Kanetsuki; Jiro Hirota; Tomohide Asai; Yasuhide Mitsumoto; Masayuki Mizuno; Toshihide Shima; Yoshihiro Kanbara; Satoko Arai; Toru Miyazaki; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2017-10-30       Impact factor: 7.527

7.  Specific features of colorectal cancer in patients with metabolic syndrome: a matched case-control analysis of 772 patients.

Authors:  Alban Zarzavadjian Le Bian; Christine Denet; Nicolas Tabchouri; Gianfranco Donatelli; Philippe Wind; Christophe Louvet; Mostefa Bennamoun; Christos Christidis; Thierry Perniceni; David Fuks; Brice Gayet
Journal:  Langenbecks Arch Surg       Date:  2018-04-27       Impact factor: 3.445

8.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

Review 9.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

10.  Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients.

Authors:  Jens U Marquardt; Kerstin Fischer; Katharina Baus; Anubha Kashyap; Shengyun Ma; Markus Krupp; Matthias Linke; Andreas Teufel; Ulrich Zechner; Dennis Strand; Snorri S Thorgeirsson; Peter R Galle; Susanne Strand
Journal:  Hepatology       Date:  2013-07-30       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.